Carbon Reduction Plan
Supplier Name: Huma Therapeutics Limited
Publication Date: 26 June 2024
Commitment to Achieving Net Zero
Huma Therapeutics Limited is committed to achieving Net Zero emissions by 2040. Our Carbon Reduction Plan delineates our current emissions data, future targets, and strategic actions to realise our environmental goals
Baseline Emissions Footprint
Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.
Our baseline emissions, calculated by an independent third party, conform to the GHG Reporting Protocol and the UK BEIS conversion factors. These calculations are based on the Financial Control emission boundary and reflect our latest emissions data.
Baseline Year: 2022
Scope 1
0**
Direct Emissions from fuel combustion in own buildings and vehicles
Scope 2
5*
Emissions from electricity & heating use in control of the company (Market-based)
Scope 3
1,013
Emissions from the corporate value chain
215.9
Total Emissions
1,018
* Our location-based scope 2 emissions for the period amounted to 39.31 tCO2e.
** NA / Too small to warrant monitoring
Current Emissions Reporting
Current Reporting Year Set as Baseline Year
Scope 1
0**
Direct Emissions from fuel combustion in own buildings and vehicles
Scope 2
5*
Emissions from electricity & heating use in control of the company (Market-based)
Scope 3
1,013
Emissions from the corporate value chain
215.9
Total Emissions
1,018
* Our location-based scope 2 emissions for the period amounted to 39.31 tCO2e.
** NA / Too small to warrant monitoring
Emissions Reduction Targets
Huma Therapeutics Limited is dedicated to achieving Net Zero emissions by 2040.
We project that our carbon emissions will decrease over the ten-year period to 590.44 tCO2e by 2032. Representing a 42% reduction.
Carbon Reduction Projects
We are currently advancing towards setting a Science-Based Target through the Science-Based Target Initiative (SBTi) platform, which will help us align our goals with the latest climate science and ensure our efforts contribute meaningfully to global emissions reduction.
We have committed to full transparency by disclosing our emissions data through the Carbon Disclosure Project (CDP), enabling us to benchmark our progress and demonstrate our commitment to environmental responsibility to our stakeholders and the wider community.
Declaration and Sign Off
This Carbon reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.
Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.
Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.
This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).
Signed on behalf of the Supplier:
26-Jun-2024 | 12:40 BST
Mark Gilder
Global Head of Legal
Huma Therapeutics Limited